CO2017004504A2 - Composición que comprende al menos un polvo seco obtenido por secado por atomización para aumentar la estabilidad de la formulación - Google Patents

Composición que comprende al menos un polvo seco obtenido por secado por atomización para aumentar la estabilidad de la formulación

Info

Publication number
CO2017004504A2
CO2017004504A2 CONC2017/0004504A CO2017004504A CO2017004504A2 CO 2017004504 A2 CO2017004504 A2 CO 2017004504A2 CO 2017004504 A CO2017004504 A CO 2017004504A CO 2017004504 A2 CO2017004504 A2 CO 2017004504A2
Authority
CO
Colombia
Prior art keywords
dry powder
formulation
stability
composition
increase
Prior art date
Application number
CONC2017/0004504A
Other languages
English (en)
Inventor
Giovanni Caponetti
Loretta Maggi
Cristina Veneziani
Laura Zanellotti
Heike Butti
Original Assignee
Eratech S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eratech S R L filed Critical Eratech S R L
Publication of CO2017004504A2 publication Critical patent/CO2017004504A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a formulaciones de inhalación de fármacos en forma de polvo seco para administración por inhalación
CONC2017/0004504A 2014-10-08 2017-05-04 Composición que comprende al menos un polvo seco obtenido por secado por atomización para aumentar la estabilidad de la formulación CO2017004504A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20141761 2014-10-08
PCT/EP2015/073188 WO2016055544A1 (en) 2014-10-08 2015-10-07 Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation

Publications (1)

Publication Number Publication Date
CO2017004504A2 true CO2017004504A2 (es) 2017-10-20

Family

ID=51904067

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0004504A CO2017004504A2 (es) 2014-10-08 2017-05-04 Composición que comprende al menos un polvo seco obtenido por secado por atomización para aumentar la estabilidad de la formulación

Country Status (14)

Country Link
US (1) US10517828B2 (es)
EP (1) EP3203983A1 (es)
JP (1) JP6919093B2 (es)
KR (1) KR102462058B1 (es)
CN (1) CN107205936B (es)
AU (2) AU2015330010A1 (es)
CA (1) CA2962531C (es)
CO (1) CO2017004504A2 (es)
EA (1) EA035740B1 (es)
IL (1) IL251472B (es)
MX (1) MX2017004476A (es)
MY (1) MY191712A (es)
WO (1) WO2016055544A1 (es)
ZA (1) ZA201703125B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2929818T3 (es) 2020-05-18 2022-12-02 Orexo Ab Nueva composición farmacéutica para la administración de fármacos
CN112125818A (zh) * 2020-09-23 2020-12-25 山东瑞博龙化工科技股份有限公司 一种制备n,n-二乙基丙烯酰胺的系统及工艺
EP4236921A1 (en) 2021-11-25 2023-09-06 Orexo AB Pharmaceutical composition comprising adrenaline
CN115400103B (zh) * 2022-09-22 2023-11-24 苏州易合医药有限公司 一种多孔性呼吸颗粒及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826783D0 (en) 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
EP1913939B1 (en) * 2000-06-27 2017-05-31 Vectura Limited Formulations for use in inhaler devices
AU2002333644A1 (en) * 2001-09-17 2003-04-01 Glaxo Group Limited Dry powder medicament formulations
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
BRPI0721256A2 (pt) * 2007-02-09 2013-03-12 Schering Corp aerossàis de fÁrmaco farmacÊuticos estÁveis
WO2011069197A1 (en) * 2009-12-08 2011-06-16 The University Of Sydney Inhalable formulations
GB201102237D0 (en) * 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
EP2682009B1 (en) * 2011-03-02 2018-10-24 Japan Tobacco, Inc. Method for producing flavoring-containing sheet for smoking article
WO2013109220A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising tiotropium, formoterol and budesonide
ES2683254T3 (es) 2012-01-25 2018-09-25 Chiesi Farmaceutici S.P.A. Formulación en polvo seca que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación
GEP201706672B (en) * 2012-07-05 2017-05-25 Arven Ilac Sanayi Ve Ticaret As Dry powder inhaler compositions comprising long acting muscorinic antagonists

Also Published As

Publication number Publication date
BR112017007182A2 (pt) 2017-12-19
AU2021200503A1 (en) 2021-02-25
MY191712A (en) 2022-07-09
CA2962531C (en) 2023-05-23
EP3203983A1 (en) 2017-08-16
AU2015330010A1 (en) 2017-04-27
WO2016055544A1 (en) 2016-04-14
CA2962531A1 (en) 2016-04-14
EA035740B1 (ru) 2020-08-03
MX2017004476A (es) 2017-11-20
ZA201703125B (en) 2020-05-27
US20170333349A1 (en) 2017-11-23
CN107205936B (zh) 2021-07-16
IL251472B (en) 2021-08-31
IL251472A0 (en) 2017-05-29
EA201700182A1 (ru) 2017-09-29
AU2021200503B2 (en) 2023-01-12
JP2017530993A (ja) 2017-10-19
US10517828B2 (en) 2019-12-31
CN107205936A (zh) 2017-09-26
JP6919093B2 (ja) 2021-08-18
KR20170093114A (ko) 2017-08-14
KR102462058B1 (ko) 2022-11-01

Similar Documents

Publication Publication Date Title
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
BR112016000937A2 (pt) formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
ECSP16059106A (es) Composiciones de liberación retardada de linaclotida
DK3328215T3 (da) Stabilt tørre probiotiske sammensætninger til særlige kostanvendelser
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
DK3107548T3 (da) Tørpulverformuleringer til inhalation
ZA201508248B (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
CO2017004504A2 (es) Composición que comprende al menos un polvo seco obtenido por secado por atomización para aumentar la estabilidad de la formulación
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
GT201600252A (es) Derivados de naftiridinadiona
BR112018002283A2 (pt) Composição para administração tópica a um sujeito, e, formulação tópica
DK3179986T3 (da) Tørpulverformuleringer til inhalation
MX371443B (es) Composiciones farmaceuticas que comprenden levocetirizina.
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
SG11201608845PA (en) Cosmetic composition containing mentha haplocalyx as active ingredient
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações
DK3107568T3 (da) Formuleringer til indgivelse til tyndtarmen
IL261929B (en) Stable pharmaceutical preparations for topical administration and their use
BR112017006613A2 (pt) composição herbicida e processo da mesma
DK2915526T3 (da) Farmaceutiske sammensætninger, der omfatter anagrelid
UY35958A (es) Derivados de quinolina como insecticidas y acaricidas